


MEDCHEM[®]FACTORY[®]

SCYNEXIS MEDCHEM-FACTORY[®] is a patented, HPLC-based system for rapid and efficient purification of compound libraries for drug discovery. Robust and reliable, MEDCHEM-FACTORY[®] has purified more than 500,000 analogs over ten years of operation.

The preparation of compound libraries for drug discovery has been a SCYNEXIS core competency since the founding of the company in 2000. SCYNEXIS synthesizes between 50,000 and 100,000 compounds every year as part of drug discovery projects using our MEDCHEM-FACTORY[®] technology. Our proprietary⁽¹⁾ High-Throughput Purification (HTP) system is a key component of this technology and allows each synthesized analog to be individually purified, analyzed, and plated in a suitable format for delivery to screening or archiving.



SCYNEXIS purifies more than 75,000 compounds per year at a scale of 5 to 20 mg per analog. Routinely, 2000-2500 compounds are purified per week, with a peak capacity of 1100 compounds per day achieved. The average success rate for libraries is 90%.

The HTP system is based on the parallel integration of HPLC and LC/MS technologies and consists of three phases: Input QC, Prep, and Final QC. The process is managed by a proprietary software system called HEOS® HTP Suite, which converts and transfers data between components, saves results to a central database and allows real-time analysis of results and progress at each stage.

In Input QC, crude reaction samples in plate format are analyzed via reverse-phase LC/MS for the target compound using methods developed by SCYNEXIS. HTP Suite captures the LC/MS data and converts the retention time of the target product into a corresponding time window for collection via prep chromatography.


In the Prep phase, the crude mixture is transferred to a preparative HPLC system. HTP suite directs the collection of the desired peak into pre-tared collection tubes based on the data collected in Input QC. The fraction tubes are then evaporated, the purified contents are diluted in a suitable solvent to the desired concentration and the solutions are transferred to 96-well plates.

In the Final QC phase, each well of the plate is sampled and the contents analyzed by reverse-phase LC/MS. The compounds meeting the pre-defined criteria are then submitted for biological screening, or redistributed as required by the particular project. The data from each stage is transferred to the HEOS® database for archiving and analysis.

Core Capabilities

- Purifies up to 2,500 samples per week
- Delivers analogs in a variety of formats
- Handles diverse structural properties
- Real time analysis of progress and results through HEOS®
- Rapid turnaround of samples

^[1] US Patent 6,387,273; US Patent 6,413,431; US Patent 6,736,975.



From Concept To Clinic With Speed And Innovation™

SCYNEXIS, Incorporated • PO Box 12878 • Research Triangle Park • North Carolina • 27709-2878 • USA • +1.919.544.8600

WWW.SCYNEXIS.COM

©Copyright 2011, SCYNEXIS, INC. From Concept To Clinic With Speed And Innovation is a trademark of SCYNEXIS, Inc.
SCYNEXIS, MEDCHEM-FACTORY and HEOS are registered trademarks of SCYNEXIS, Inc.